Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 +0.33%95 Return-on-Tangible-Equity is 12.48% as of Jun. 2026, which is 28% below its 10-year median of 17.32. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 756 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks better than 69.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Autobio Diagnostics Co's annualized net income for the quarter that ended in Jun. 2026 was ¥1,043 Mil. Autobio Diagnostics Co's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ¥8,354 Mil. Therefore, Autobio Diagnostics Co's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 12.48%.
The historical rank and industry rank for Autobio Diagnostics Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603658'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.98 Med: 17.32 Max: 42.25
Current: 11.98
During the past 13 years, Autobio Diagnostics Co's highest Return-on-Tangible-Equity was 42.25%. The lowest was 11.98%. And the median was 17.32%.
SHSE:603658's Return-on-Tangible-Equity is ranked better than 69.05% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 4.965
vs SHSE:603658: 11.98
Autobio Diagnostics Co (SHSE:603658) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Autobio Diagnostics Co Return-on-Tangible-Equity Related Terms
Autobio Diagnostics Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Autobio Diagnostics Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co Return-on-Tangible-Equity Chart
SHSE:603658 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.48% mean?
Autobio Diagnostics Co (SHSE:603658) has a Return-on-Tangible-Equity of 12.48% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Autobio Diagnostics Co and its competitors. This is 28% below median its historical median of 17.32. Over the past decade, Autobio Diagnostics Co's Return-on-Tangible-Equity has ranged from 11.98 to 42.25. According to the industry distribution chart, Autobio Diagnostics Co ranks #234 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 31%.
Is Autobio Diagnostics Co's Return-on-Tangible-Equity too high?
Autobio Diagnostics Co's current Return-on-Tangible-Equity of 12.48% is 28% below median its 10-year median of 17.32. Over the past 10 years, this metric has ranged from a low of 11.98 to a high of 42.25. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.97. Autobio Diagnostics Co's value of 12.48% is 151.4% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #234 out of 756 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #234 out of 756 companies for Return-on-Tangible-Equity. This puts Autobio Diagnostics Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.97. Autobio Diagnostics Co's value of 12.48% is 151.4% above this benchmark. Historically, Autobio Diagnostics Co's own Return-on-Tangible-Equity has ranged from 11.98 to 42.25 over the past decade. While the company's 10-year median is 17.32 vs. the industry median of 4.97, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.97, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current Return-on-Tangible-Equity of 12.48% is 151.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current Return-on-Tangible-Equity is 12.48%, which is 28% below median its own 10-year median of 17.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.31, compared to a current price of ¥33.52 — trading 16.8% below its estimated fair value. The current Return-on-Tangible-Equity is 12.48%, which is 28% below median its 10-year median of 17.32 and 151.4% above the Medical Devices & Instruments industry median of 4.97. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current Return-on-Tangible-Equity is 12.48% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥33.52 is trading 16.8% below its estimated GF Value™ of ¥40.31.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
Return-on-Tangible-Equity: 12.48% (28% below median its 10-year median of 17.32)
GF Value™: ¥40.31 vs. price of ¥33.52 (16.8% below fair value)
Industry Position: 151.4% above the Medical Devices & Instruments median (#234 of 756)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
